FINWIRES · TerminalLIVE
FINWIRES

$BSX

49 stories mentioning BSX

Every FINWIRES story that references BSX, newest first.

US Markets

Boston Scientific Tops First-Quarter Results, Cuts Full-Year Outlook

Boston Scientific's (BSX) first-quarter results exceeded Wall Street's estimates, while the medical device supplier lowered its full-year guidance on Wednesday.For the March quarter, adjusted earnings grew to $0.80 from $0.75 a year earlier, while net sales rose nearly 12% to $5.20 billion. The FactSet-polled consensus estimates are for $0.79 and $5.17 billion, respectively.First-quarter sales in the cardiovascular business surged 13.5% year over year to $3.50 billion. The MedSurg division grew 7.8% to $1.70 billion with double-digit gains in neuromodulation. The company logged revenue growth across all regions, led by a 19% increase in the Latin America and Caribbean.Shares of Boston Scientific were up 9.2% in Wednesday trade. The stock has plunged 32% so far this year.The company lowered its 2026 net sales growth outlook to between 7% and 8.5% from a 10.5% to 11.5% increase previously expected. The company now estimates adjusted EPS of $3.34 to $3.41, down from the prior guidance of $3.43 to $3.49. The market expects $22.24 billion in full-year revenue and $3.45 of EPS.For the second quarter, the company guided adjusted EPS at $0.82 to $0.84 on sales growth of 5.5% to 7.5%. Analysts expect EPS of $0.86 and sales of $5.55 billion."Second quarter is our toughest quarter of the year," Chief Executive Mike Mahoney said on an earnings call, according to a FactSet transcript.Price: $64.77, Change: $+5.25, Percent Change: +8.82%

$BSX
Wire

Piper Sandler Adjusts Boston Scientific Price Target to $90 From $105, Maintains Overweight Rating

Boston Scientific (BSX) has an average rating of Buy and mean price target of $96.45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $64.59, Change: $+5.07, Percent Change: +8.52%

$BSX
Sectors

Sector Update: Health Care Stocks Edge Higher Premarket Wednesday

Health care stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4% and the iShares Biotechnology ETF (IBB) 0.3% higher.Boston Scientific (BSX) shares were up more than 5% after the company reported higher Q1 adjusted earnings and net sales.Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical have expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that could be valued at more than $8 billion, Reuters reported, citing people familiar with the matter. Inhibrx Biosciences stock was up more than 48% pre-bell.Healthcare Services Group (HCSG) shares were up more than 22% after the company reported higher Q1 earnings and revenue.

$BSX$HCSG$IBB$INBX$MRK$XLV
Sectors

Sector Update: Health Care

Health care stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.5% and the iShares Biotechnology ETF (IBB) 0.3% higher.Boston Scientific (BSX) shares were up more than 5% after the company reported higher Q1 adjusted earnings and net sales.

$BSX
Research

Research Alert: Boston Scientific Q1 2026: Strong Cardiovascular Growth, Solid U.s. Performance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Boston Scientific delivered solid Q1 2026 results with net sales of $5.203B (+11.6% reported, +9.4% organic), continuing double-digit growth though at a more normalized pace versus exceptional 2025 levels. The quarter showed broad-based momentum with Cardiovascular generating $3.503B (+13.5% reported, +11.2% organic) and MedSurg contributing $1.701B (+7.8% reported, +5.7% organic). We view sustained Cardiovascular growth favorably, led by FARAPULSE adoption and structural heart solutions, underscoring leadership in high-growth markets. Management provided 2026 guidance with organic sales growth of 6.5%-8.0% and adjusted EPS of $3.34-$3.41, implying further deceleration but maintaining an above-market trajectory. We believe U.S. market strength with $3.284B in revenues (+10.9%) and standout Neuromodulation performance (+17.4% growth) support our positive outlook, while the active innovation pipeline with CHAMPION-AF trial successes positions Boston Scientific to sustain its competitive advantages.

$BSX
US Markets

Stocks Rise Pre-Bell as Trump Extends Iran Ceasefire; Tesla Earnings On Deck

The main US stock measures were trending higher in Wednesday's premarket activity after President Donald Trump extended the two-week US ceasefire with Iran, while traders await the latest round of corporate earnings, including results from Tesla (TSLA).The S&P 500 rose 0.6%, the Dow Jones Industrial Average increased 0.5% and the Nasdaq added 0.7% before the opening bell. The indexes finished Tuesday trading lower for the second consecutive session.In a social media post on Tuesday, Trump announced the extension of the two-week US ceasefire deal with Iran, citing a request by Pakistan's Prime Minister Shehbaz Sharif and Field Marshal Asim Munir. The truce was announced on April 7. The naval blockade of Iranian ports will continue, according to Trump."We have been asked to hold our attack on the country of Iran until such time as their leaders and representatives can come up with a unified proposal," Trump said in the post. "I have therefore directed our military to continue the blockade and, in all other respects, remain ready and able, and will therefore extend the ceasefire until such time as their proposal is submitted, and discussions are concluded, one way or the other."Iranian state news outlet Tasnim reported that negotiators from Tehran won't participate in further peace talks with their US counterparts, according to CNBC. US Vice President JD Vance's expected trip to Islamabad for peace talks with Iran has been called off, CNN reported, citing a White House official.West Texas Intermediate crude oil inclined 1.3% to $90.83 a barrel in premarket action, while Brent rose 1.1% to $99.56.The Trump administration is evaluating a potential extension of a maritime shipping waiver to make it easier to move oil and gasoline between US ports, Bloomberg News reported Wednesday, citing people familiar with the matter.Electric vehicle giant Tesla is scheduled to release its latest quarterly results after the markets close, along with International Business Machines (IBM) and Texas Instruments (TXN). GE Vernova (GEV), Philip Morris International (PM), AT&T (T), Boeing (BA), Boston Scientific (BSX) and Elevance Health (ELV) post earnings before the bell, among others.Intuitive Surgical (ISRG) shares advanced 2% pre-bell as the company lifted the full-year procedure growth outlook of its da Vinci robotic surgery system and reported better-than-expected first-quarter results. Advanced Micro Devices (AMD) gained 2%.Kevin Warsh said Tuesday that the Federal Reserve, under his leadership, would be independent from the White House, CNBC reported. Warsh, who is Trump's Fed chair nominee, made the remarks at his Senate Banking Committee confirmation hearing.Treasury yields were moving down before the open, with the two-year rate retreating 0.8 basis points to 3.77% and the 10-year rate off 1 basis point to 4.28%.Official data on Tuesday showed that retail sales last month logged the largest rise since March 2025 amid a surge in spending at gasoline stations as the Middle East conflict boosted energy prices.Wednesday's economic calendar has the weekly mortgage applications bulletin at 7 am ET, followed by the weekly EIA domestic petroleum inventories report at 10:30 am.Gold rose 1.1% to $4,769 per troy ounce, while bitcoin climbed 3.9% to $78,172.

Dow JonesNasdaq CompositeS&P 500$AMD$BA$BSX$ELV$GEV$IBM$ISRG$PM$T$TSLA$TXN
Wire

Barclays Lowers Price Target on Boston Scientific to $100 From $124, Maintains Overweight Rating

Boston Scientific (BSX) has an average rating of buy and mean price target of $97.23, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $61.58, Change: $+0.59, Percent Change: +0.97%

$BSX
Wire

BTIG Research Adjusts Boston Scientific Price Target to $90 From $110, Maintains Buy Rating

Boston Scientific (BSX) has an average rating of Buy and mean price target of $98.71, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $61.97, Change: $+0.18, Percent Change: +0.29%

$BSX
Wire

Mizuho Adjusts Price Target on Boston Scientific to $90 From $115, Maintains Outperform Rating

Boston Scientific (BSX) has an average rating of buy and mean price target of $98.71, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $62.46, Change: $+0.67, Percent Change: +1.08%

$BSX

Showing 41-49 of 49